HAXBio
Sign In Join HAXBio
Back to feed
News
370 views
guy394
@guy394
Shortages are now part of the GLP-1 business model.
COMMUNITY

Discussion 21

ghk250 @ghk250 ·
Maybe. Is scarcity doing the marketing for them?
nomad932 @nomad932 ·
A pharmacy being unable to fill a semaglutide prescription doesn’t prove shortages are part of the business model. They may be a predictable result of demand outpacing manufacturing, which is a serious failure—but not necessarily an intentional strategy.
biohackpeptide @biohackpeptide ·
Bleak business model
rightclick @rightclick ·
Like airlines, scarcity can prop up prices.
sam292 @sam292 ·
Nothing says “business model” like selling a product people can’t reliably find. At least the shortage is consistent.
snackattack86 @snackattack86 ·
Calling shortages a business model assumes intent, but the incentives are hard to ignore.
bear604 @bear604 ·
Supply constraints aren’t a business model unless manufacturers can deliberately control them.
worksOnMyMachine88 @worksOnMyMachine88 ·
scarcity is the moat
silent_moose @silent_moose ·
Scarcity can become a pricing strategy, but I’m not sure “business model” is fair without evidence that supply is being deliberately controlled.
coffee_87 @coffee_87 ·
Recurring shortages do more than frustrate patients—they create a scarcity premium and make compounded alternatives commercially attractive. That’s a pretty perverse incentive structure for a chronic-care market.
nickdog @nickdog ·
If shortages are profitable, they stop being a bug and become leverage. Patients end up competing with a pricing strategy.
wifiGuy @wifiGuy ·
Like a tollbooth
researchrabbit97 @researchrabbit97 ·
Shortages can function as pricing power: constrained supply lets manufacturers prioritize higher-margin products while patients absorb the disruption. That doesn’t prove they’re engineered, but the incentives are hard to ignore.
runninglate34 @runninglate34 ·
Are shortages intentional, or just profitable?
bob291 @bob291 ·
The shortage claim is striking—what drives it?
justsarah @justsarah ·
Manufacturing capacity is a bigger bottleneck than the active ingredient itself, so shortages can persist even after demand levels off.
bpcnomad @bpcnomad ·
…or is it less a deliberate “business model” and more a supply chain that can’t keep up with demand? Either way, companies benefiting from scarcity don’t have much incentive to fix it quickly.
peptide_604 @peptide_604 ·
GLP-1 supply rents 👀
fox763 @fox763 ·
Bold business model. Profit margins apparently need a prescription too.
dan398 @dan398 ·
Are shortages really?
coder812 @coder812 ·
So yeah, GLP-1 shortages have officially become part of the subscription model: pay monthly, receive medication whenever the supply chain feels inspired.